Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.

EISAI LAUNCHES SNAIL VENOM PAIN DRUG IN BRITAIN

A new pain drug based on the venom of a deadly sea snail was launched in Britain
on Monday, offering hope to patients with chronic pain who do not respond to
or cannot tolerate treatments like morphine. Japanese drugmaker Eisai Co Ltd,
which acquired European rights to Prialt from Ireland's Elan Corp Plc, is marketing
the medicine first in Britain before rolling it out in other European markets.